Overview

• Regulators approved the first glucose monitoring system in the U.S. explicitly cleared for weight loss.
• The OTC rollout integrates Dexcom’s Stelo CGM with Signos’ AI to translate glucose readings into individualized lifestyle recommendations.
• Consumers can enroll without a prescription or BMI requirement through a Signos membership.
• Plans cost $139 for three months or $129 for six months with sensors included, and insurers do not yet cover the service.
• Signos says the platform can complement GLP-1 drugs or bariatric care and that inventory and software capacity have been scaled following clearance.